Data from Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors Article Swipe
Hon Kit Wong
,
Johanna Lahdenranta
,
Walid S. Kamoun
,
Annie W. Chan
,
Andrea I. McClatchey
,
Scott R. Plotkin
,
Rakesh K. Jain
,
Emmanuelle di Tomaso
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.c.6501545.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.c.6501545.v1
Patients with bilateral vestibular schwannomas associated with neurofibromatosis type 2 (NF2) experience significant morbidity such as complete hearing loss. We have recently shown that treatment with bevacizumab provided tumor stabilization and hearing recovery in a subset of NF2 patients with progressive disease. In the current study, we used two animal models to identify the mechanism of action of anti–vascular endothelial growth factor (VEGF) therapy in schwannomas. The human HEI193 and murine Nf2−/− cell lines were implanted between the pia and arachnoid meninges as well as in the sciatic nerve to mimic central and peripheral schwannomas. Mice were treated with bevacizumab (10 mg/kg/wk i.v.) or vandetanib (50 mg/kg/d orally) to block the VEGF pathway. Using intravital and confocal microscopy, together with whole-body imaging, we measured tumor growth delay, survival rate, as well as blood vessel structure and function at regular intervals. In both models, tumor vessel diameter, length/surface area density, and permeability were significantly reduced after treatment. After 2 weeks of treatment, necrosis in HEI193 tumors and apoptosis in Nf2−/− tumors were significantly increased, and the tumor growth rate decreased by an average of 50%. The survival of mice bearing intracranial schwannomas was extended by at least 50%. This study shows that anti-VEGF therapy normalizes the vasculature of schwannoma xenografts in nude mice and successfully controls the tumor growth, probably by reestablishing a natural balance between VEGF and semaphorin 3 signaling. Cancer Res; 70(9); 3483–93. ©2010 AACR.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/0008-5472.c.6501545.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4392724714
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4392724714Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/0008-5472.c.6501545.v1Digital Object Identifier
- Title
-
Data from Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related TumorsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-30Full publication date if available
- Authors
-
Hon Kit Wong, Johanna Lahdenranta, Walid S. Kamoun, Annie W. Chan, Andrea I. McClatchey, Scott R. Plotkin, Rakesh K. Jain, Emmanuelle di TomasoList of authors in order
- Landing page
-
https://doi.org/10.1158/0008-5472.c.6501545.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/0008-5472.c.6501545.v1Direct OA link when available
- Concepts
-
Neurofibromatosis, Medicine, Vascular endothelial growth factor, Cancer research, VEGF receptors, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4392724714 |
|---|---|
| doi | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| ids.doi | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| ids.openalex | https://openalex.org/W4392724714 |
| fwci | 0.0 |
| type | preprint |
| title | Data from Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11173 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.996999979019165 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2728 |
| topics[0].subfield.display_name | Neurology |
| topics[0].display_name | Neurofibromatosis and Schwannoma Cases |
| topics[1].id | https://openalex.org/T11054 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9693999886512756 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Adrenal and Paraganglionic Tumors |
| topics[2].id | https://openalex.org/T12108 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9535999894142151 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Management of metastatic bone disease |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778984943 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6398382186889648 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q847605 |
| concepts[0].display_name | Neurofibromatosis |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.5574648976325989 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2777025900 |
| concepts[2].level | 3 |
| concepts[2].score | 0.49174192547798157 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q29725 |
| concepts[2].display_name | Vascular endothelial growth factor |
| concepts[3].id | https://openalex.org/C502942594 |
| concepts[3].level | 1 |
| concepts[3].score | 0.3983701169490814 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[3].display_name | Cancer research |
| concepts[4].id | https://openalex.org/C167734588 |
| concepts[4].level | 2 |
| concepts[4].score | 0.2734468877315521 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q4356503 |
| concepts[4].display_name | VEGF receptors |
| concepts[5].id | https://openalex.org/C142724271 |
| concepts[5].level | 1 |
| concepts[5].score | 0.237010657787323 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[5].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/neurofibromatosis |
| keywords[0].score | 0.6398382186889648 |
| keywords[0].display_name | Neurofibromatosis |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.5574648976325989 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/vascular-endothelial-growth-factor |
| keywords[2].score | 0.49174192547798157 |
| keywords[2].display_name | Vascular endothelial growth factor |
| keywords[3].id | https://openalex.org/keywords/cancer-research |
| keywords[3].score | 0.3983701169490814 |
| keywords[3].display_name | Cancer research |
| keywords[4].id | https://openalex.org/keywords/vegf-receptors |
| keywords[4].score | 0.2734468877315521 |
| keywords[4].display_name | VEGF receptors |
| keywords[5].id | https://openalex.org/keywords/pathology |
| keywords[5].score | 0.237010657787323 |
| keywords[5].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1158/0008-5472.c.6501545.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5018467186 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-0049-8454 |
| authorships[0].author.display_name | Hon Kit Wong |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Hon Kit Wong |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5045177125 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-2172-5399 |
| authorships[1].author.display_name | Johanna Lahdenranta |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Johanna Lahdenranta |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5054359239 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Walid S. Kamoun |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Walid S. Kamoun |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5053515304 |
| authorships[3].author.orcid | https://orcid.org/0009-0005-3157-647X |
| authorships[3].author.display_name | Annie W. Chan |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Annie W. Chan |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5064644062 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-6150-3619 |
| authorships[4].author.display_name | Andrea I. McClatchey |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Andrea I. McClatchey |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5059797681 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6109-6419 |
| authorships[5].author.display_name | Scott R. Plotkin |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Scott R. Plotkin |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5015585176 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-7571-3548 |
| authorships[6].author.display_name | Rakesh K. Jain |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Rakesh K. Jain |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5019864381 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Emmanuelle di Tomaso |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Emmanuelle di Tomaso |
| authorships[7].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11173 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.996999979019165 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2728 |
| primary_topic.subfield.display_name | Neurology |
| primary_topic.display_name | Neurofibromatosis and Schwannoma Cases |
| related_works | https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725, https://openalex.org/W2148612803 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/0008-5472.c.6501545.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| primary_location.id | doi:10.1158/0008-5472.c.6501545.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/0008-5472.c.6501545.v1 |
| publication_date | 2023-03-30 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 9, 157 |
| abstract_inverted_index.3 | 228 |
| abstract_inverted_index.a | 34, 221 |
| abstract_inverted_index.In | 42, 140 |
| abstract_inverted_index.We | 19 |
| abstract_inverted_index.an | 180 |
| abstract_inverted_index.as | 15, 82, 84, 129, 131 |
| abstract_inverted_index.at | 137, 194 |
| abstract_inverted_index.by | 179, 193, 219 |
| abstract_inverted_index.in | 33, 64, 85, 162, 167, 209 |
| abstract_inverted_index.of | 36, 55, 57, 159, 182, 186, 206 |
| abstract_inverted_index.or | 103 |
| abstract_inverted_index.to | 51, 89, 108 |
| abstract_inverted_index.we | 46, 122 |
| abstract_inverted_index.(10 | 100 |
| abstract_inverted_index.(50 | 105 |
| abstract_inverted_index.NF2 | 37 |
| abstract_inverted_index.The | 66, 184 |
| abstract_inverted_index.and | 30, 69, 79, 92, 115, 135, 149, 165, 173, 212, 226 |
| abstract_inverted_index.pia | 78 |
| abstract_inverted_index.the | 43, 53, 77, 86, 110, 174, 204, 215 |
| abstract_inverted_index.two | 48 |
| abstract_inverted_index.was | 191 |
| abstract_inverted_index.50%. | 183, 196 |
| abstract_inverted_index.Mice | 95 |
| abstract_inverted_index.Res; | 231 |
| abstract_inverted_index.This | 197 |
| abstract_inverted_index.VEGF | 111, 225 |
| abstract_inverted_index.area | 147 |
| abstract_inverted_index.both | 141 |
| abstract_inverted_index.cell | 72 |
| abstract_inverted_index.have | 20 |
| abstract_inverted_index.mice | 187, 211 |
| abstract_inverted_index.nude | 210 |
| abstract_inverted_index.rate | 177 |
| abstract_inverted_index.such | 14 |
| abstract_inverted_index.that | 23, 200 |
| abstract_inverted_index.type | 8 |
| abstract_inverted_index.used | 47 |
| abstract_inverted_index.well | 83, 130 |
| abstract_inverted_index.were | 74, 96, 151, 170 |
| abstract_inverted_index.with | 1, 6, 25, 39, 98, 119 |
| abstract_inverted_index.(NF2) | 10 |
| abstract_inverted_index.After | 156 |
| abstract_inverted_index.Using | 113 |
| abstract_inverted_index.after | 154 |
| abstract_inverted_index.block | 109 |
| abstract_inverted_index.blood | 132 |
| abstract_inverted_index.human | 67 |
| abstract_inverted_index.i.v.) | 102 |
| abstract_inverted_index.least | 195 |
| abstract_inverted_index.lines | 73 |
| abstract_inverted_index.loss. | 18 |
| abstract_inverted_index.mimic | 90 |
| abstract_inverted_index.nerve | 88 |
| abstract_inverted_index.rate, | 128 |
| abstract_inverted_index.shown | 22 |
| abstract_inverted_index.shows | 199 |
| abstract_inverted_index.study | 198 |
| abstract_inverted_index.tumor | 28, 124, 143, 175, 216 |
| abstract_inverted_index.weeks | 158 |
| abstract_inverted_index.(VEGF) | 62 |
| abstract_inverted_index.70(9); | 232 |
| abstract_inverted_index.Cancer | 230 |
| abstract_inverted_index.HEI193 | 68, 163 |
| abstract_inverted_index.action | 56 |
| abstract_inverted_index.animal | 49 |
| abstract_inverted_index.delay, | 126 |
| abstract_inverted_index.factor | 61 |
| abstract_inverted_index.growth | 60, 125, 176 |
| abstract_inverted_index.models | 50 |
| abstract_inverted_index.murine | 70 |
| abstract_inverted_index.study, | 45 |
| abstract_inverted_index.subset | 35 |
| abstract_inverted_index.tumors | 164, 169 |
| abstract_inverted_index.vessel | 133, 144 |
| abstract_inverted_index.©2010 | 234 |
| abstract_inverted_index.average | 181 |
| abstract_inverted_index.balance | 223 |
| abstract_inverted_index.bearing | 188 |
| abstract_inverted_index.between | 76, 224 |
| abstract_inverted_index.central | 91 |
| abstract_inverted_index.current | 44 |
| abstract_inverted_index.growth, | 217 |
| abstract_inverted_index.hearing | 17, 31 |
| abstract_inverted_index.mg/kg/d | 106 |
| abstract_inverted_index.models, | 142 |
| abstract_inverted_index.natural | 222 |
| abstract_inverted_index.orally) | 107 |
| abstract_inverted_index.reduced | 153 |
| abstract_inverted_index.regular | 138 |
| abstract_inverted_index.sciatic | 87 |
| abstract_inverted_index.therapy | 63, 202 |
| abstract_inverted_index.treated | 97 |
| abstract_inverted_index.complete | 16 |
| abstract_inverted_index.confocal | 116 |
| abstract_inverted_index.controls | 214 |
| abstract_inverted_index.density, | 148 |
| abstract_inverted_index.disease. | 41 |
| abstract_inverted_index.extended | 192 |
| abstract_inverted_index.function | 136 |
| abstract_inverted_index.identify | 52 |
| abstract_inverted_index.imaging, | 121 |
| abstract_inverted_index.measured | 123 |
| abstract_inverted_index.meninges | 81 |
| abstract_inverted_index.mg/kg/wk | 101 |
| abstract_inverted_index.necrosis | 161 |
| abstract_inverted_index.pathway. | 112 |
| abstract_inverted_index.patients | 38 |
| abstract_inverted_index.probably | 218 |
| abstract_inverted_index.provided | 27 |
| abstract_inverted_index.recently | 21 |
| abstract_inverted_index.recovery | 32 |
| abstract_inverted_index.survival | 127, 185 |
| abstract_inverted_index.together | 118 |
| abstract_inverted_index.anti-VEGF | 201 |
| abstract_inverted_index.apoptosis | 166 |
| abstract_inverted_index.arachnoid | 80 |
| abstract_inverted_index.bilateral | 2 |
| abstract_inverted_index.decreased | 178 |
| abstract_inverted_index.diameter, | 145 |
| abstract_inverted_index.implanted | 75 |
| abstract_inverted_index.mechanism | 54 |
| abstract_inverted_index.morbidity | 13 |
| abstract_inverted_index.structure | 134 |
| abstract_inverted_index.treatment | 24 |
| abstract_inverted_index.3483–93. | 233 |
| abstract_inverted_index.associated | 5 |
| abstract_inverted_index.experience | 11 |
| abstract_inverted_index.increased, | 172 |
| abstract_inverted_index.intervals. | 139 |
| abstract_inverted_index.intravital | 114 |
| abstract_inverted_index.normalizes | 203 |
| abstract_inverted_index.peripheral | 93 |
| abstract_inverted_index.schwannoma | 207 |
| abstract_inverted_index.semaphorin | 227 |
| abstract_inverted_index.signaling. | 229 |
| abstract_inverted_index.treatment, | 160 |
| abstract_inverted_index.treatment. | 155 |
| abstract_inverted_index.vandetanib | 104 |
| abstract_inverted_index.vestibular | 3 |
| abstract_inverted_index.whole-body | 120 |
| abstract_inverted_index.xenografts | 208 |
| abstract_inverted_index.bevacizumab | 26, 99 |
| abstract_inverted_index.endothelial | 59 |
| abstract_inverted_index.microscopy, | 117 |
| abstract_inverted_index.progressive | 40 |
| abstract_inverted_index.schwannomas | 4, 190 |
| abstract_inverted_index.significant | 12 |
| abstract_inverted_index.vasculature | 205 |
| abstract_inverted_index.intracranial | 189 |
| abstract_inverted_index.permeability | 150 |
| abstract_inverted_index.schwannomas. | 65, 94 |
| abstract_inverted_index.successfully | 213 |
| abstract_inverted_index.significantly | 152, 171 |
| abstract_inverted_index.stabilization | 29 |
| abstract_inverted_index.length/surface | 146 |
| abstract_inverted_index.reestablishing | 220 |
| abstract_inverted_index.anti–vascular | 58 |
| abstract_inverted_index.neurofibromatosis | 7 |
| abstract_inverted_index.AACR.</p></div> | 235 |
| abstract_inverted_index.<div>Abstract<p>Patients | 0 |
| abstract_inverted_index.<i>Nf2</i><sup>−/−</sup> | 71, 168 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.40790432 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |